Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese Urological Association

Authors

  • Eiji Kikuchi,

    1. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association,
    2. Department of Urology, Keio University School of Medicine, Tokyo,
    Search for more papers by this author
  • Hiroyuki Fujimoto,

    1. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association,
    2. Urology Division, National Cancer Center Hospital, Tokyo,
    Search for more papers by this author
  • Yoichi Mizutani,

    1. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association,
    2. Department of Urology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto,
    Search for more papers by this author
  • Eijiro Okajima,

    1. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association,
    2. Department of Urology, Nara Medical University, Nara,
    Search for more papers by this author
  • Hiroshi Koga,

    1. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association,
    2. Department of Urology, Faculty of Medical Sciences, Kyushu University, Fukuoka,
    Search for more papers by this author
  • Shiro Hinotsu,

    1. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association,
    2. Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaragi, and
    Search for more papers by this author
  • Nobuo Shinohara,

    1. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association,
    2. Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
    Search for more papers by this author
  • Mototsugu Oya,

    1. Department of Urology, Keio University School of Medicine, Tokyo,
    Search for more papers by this author
  • Tsuneharu Miki,

    1. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association,
    2. Department of Urology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto,
    Search for more papers by this author
  • the Cancer Registration Committee of the Japanese Urological Association

    Search for more papers by this author
    • Members of the Cancer Registration Committee of the Japanese Urological Association: Tsuneharu Miki, Department of Urology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine; Tomoaki Fujioka, Department of Urology, Iwate Medical University; Tomohiko Ichikawa, Department of Urology, Graduate School of Medicine, Chiba University; Seiji Naito, Department of Urology, Faculty of Medical Sciences, Kyushu University; Kenjiro Kohri, Department of Urology, Graduate School of Medical Sciences, Nagoya City University; Hideyuki Akaza, Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba; Hiroyuki Fujimoto, Urology Division, National Cancer Center Hospital; Yoichi Mizutani, Department of Urology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine; Tadao Kakizoe, National Cancer Center; Akihiko Okuyama, Department of Urology, Graduate School of Medicine, Osaka University.

Errata

This article is corrected by:

  1. Errata: Corrigenda Volume 16, Issue 4, 430, Article first published online: 8 April 2009

Eiji Kikuchi md, Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Email: eiji-k@kb3.so-net.ne.jp

Abstract

Objective:  To characterize the clinical outcome in a large contemporary series of Japanese patients with newly diagnosed Ta, T1 non-muscle invasive bladder cancer who underwent transurethral bladder tumor resection with or without intravesical chemotherapy or Bacillus Calmette-Guérin (BCG) therapy.

Methods:  We developed a database incorporating newly diagnosed non-muscle invasive bladder cancer data and outcomes from a Japanese bladder cancer registry between 1999 and 2001 and identified a study population of 3237 consecutive patients who had complete data based on pathological features. Median patient age was 69.9 years.

Results:  The 1-year, 3-year, and 5-year overall recurrence-free survival rates were 77.0%, 61.3%, and 52.8%, respectively. In multivariate analyses, the multiplicity of bladder tumors, tumor size greater than 3 cm, pathological stage T1, tumor grade G3, and the absence of adjuvant intravesical instillation were independent risk factors for tumor recurrence. Overall, 1710 patients (52.8%) received intravesical instillation; chemotherapy in 1314 (76.8%) and BCG treatment in 396 (23.2%). In patients treated with intravesical chemotherapy in which an anthracycline chemo-agent was used in 90.5% of the cases, multivariate analyses demonstrated that male gender, multiple bladder tumors, a tumor size greater than 3 cm, and pathological stage T1 were associated with tumor recurrence.

Conclusions:  The accumulation and analysis of data from the Japanese National Bladder Cancer Registry made it possible to determine the clinical characteristics, management trends, and survival rates for the period studied. Further study with a dataset created from longer follow-up data would be warranted to analyze tumor progression and disease survival.

Ancillary